Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Will Hikma deliver good news concerning its generics business?
Thursday 17 August
FTSE 250 stock Hikma Pharmaceuticals (HIK) has had a difficult year after the launch of its generic version of GlaxoSmithKline’s (GSK) Advair Diskus was delayed and full year earnings guidance was downgraded in May.
Investors should look for updates about when the launch could happen and whether the traditional oral generics business is improving when Hikma reports half year results on 17 August.